A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved res...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Linch, D. C., Vaughan Hudson, B., Hancock, B. W., Hoskin, P. J., Cunningham, D. C., Newland, A. C., Milligan, D. W., Stevenson, P. A., Wood, J. K., MacLennan, K. A., Anderson, L., Gregory, W. M., Vaughan Hudson, G.
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 1996
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074593/
https://ncbi.nlm.nih.gov/pubmed/8688344
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים